Characterization of myelodysplastic syndromes hematopoietic stem and progenitor cells using mass cytometry. 2023

Costa Bachas, and Carolien Duetz, and Margot F van Spronsen, and Jan Verhoeff, and Juan J Garcia Vallejo, and Joop H Jansen, and Jacqueline Cloos, and Theresia M Westers, and Arjan A van de Loosdrecht
Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

Myelodysplastic syndromes (MDS) at risk of transformation to acute myeloid leukemia (AML) are difficult to identify. The bone marrows of MDS patients harbor specific hematopoietic stem and progenitor cell (HSPC) abnormalities that may be associated with sub-types and risk-groups. Leukemia-associated characteristics of such cells may identify MDS patients at risk of progression to AML and provide insight in the pathobiology of MDS. Bone marrow samples from healthy donors (n = 10), low risk (n = 12) and high risk (n = 13) MDS patients were collected, in addition, AML samples for 5 out of 6 MDS patients that progressed. Mass cytometry was applied to assess expression of stem cell subset and leukemia-associated immunophenotype markers. We analyzed the data using FlowSOM to cluster cells with similar expression of 10 commonly used stem cell markers. Metaclusters (n = 20) of these clusters represented populations of cells with a related phenotype, largely resembling known stem cell subsets. Within specific subsets, intra-cellular expression levels of pCREB, IkBα, or pS6 differed significantly between healthy bone marrow (HBM) and MDS or consecutive secondary AML samples. CD34, CD44, and CD49f expression was significantly increased in high risk MDS and AML-associated metaclusters. We identified MDS/sAML cells with aberrant phenotypes when compared to HBM. Such cells were observed in clusters of both primary MDS and secondary AML samples. High-dimensional mass cytometry and computational data analyses enabled characterization of HSPC subsets in MDS and identification of leukemia stem cell populations based on their immunophenotype. Stem cells in MDS that display leukemia-associated features may predict the risk of developing AML.

UI MeSH Term Description Entries
D009190 Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA. Dysmyelopoietic Syndromes,Hematopoetic Myelodysplasia,Dysmyelopoietic Syndrome,Hematopoetic Myelodysplasias,Myelodysplasia, Hematopoetic,Myelodysplasias, Hematopoetic,Myelodysplastic Syndrome,Syndrome, Dysmyelopoietic,Syndrome, Myelodysplastic,Syndromes, Dysmyelopoietic,Syndromes, Myelodysplastic
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell
D006412 Hematopoietic Stem Cells Progenitor cells from which all blood cells derived. They are found primarily in the bone marrow and also in small numbers in the peripheral blood. Colony-Forming Units, Hematopoietic,Progenitor Cells, Hematopoietic,Stem Cells, Hematopoietic,Hematopoietic Progenitor Cells,Cell, Hematopoietic Progenitor,Cell, Hematopoietic Stem,Cells, Hematopoietic Progenitor,Cells, Hematopoietic Stem,Colony Forming Units, Hematopoietic,Colony-Forming Unit, Hematopoietic,Hematopoietic Colony-Forming Unit,Hematopoietic Colony-Forming Units,Hematopoietic Progenitor Cell,Hematopoietic Stem Cell,Progenitor Cell, Hematopoietic,Stem Cell, Hematopoietic,Unit, Hematopoietic Colony-Forming,Units, Hematopoietic Colony-Forming
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D015470 Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES. Leukemia, Myelogenous, Acute,Leukemia, Nonlymphocytic, Acute,Myeloid Leukemia, Acute,Nonlymphocytic Leukemia, Acute,ANLL,Acute Myelogenous Leukemia,Acute Myeloid Leukemia,Acute Myeloid Leukemia with Maturation,Acute Myeloid Leukemia without Maturation,Leukemia, Acute Myelogenous,Leukemia, Acute Myeloid,Leukemia, Myeloblastic, Acute,Leukemia, Myelocytic, Acute,Leukemia, Myeloid, Acute, M1,Leukemia, Myeloid, Acute, M2,Leukemia, Nonlymphoblastic, Acute,Myeloblastic Leukemia, Acute,Myelocytic Leukemia, Acute,Myelogenous Leukemia, Acute,Myeloid Leukemia, Acute, M1,Myeloid Leukemia, Acute, M2,Nonlymphoblastic Leukemia, Acute,Acute Myeloblastic Leukemia,Acute Myeloblastic Leukemias,Acute Myelocytic Leukemia,Acute Myelocytic Leukemias,Acute Myelogenous Leukemias,Acute Myeloid Leukemias,Acute Nonlymphoblastic Leukemia,Acute Nonlymphoblastic Leukemias,Acute Nonlymphocytic Leukemia,Acute Nonlymphocytic Leukemias,Leukemia, Acute Myeloblastic,Leukemia, Acute Myelocytic,Leukemia, Acute Nonlymphoblastic,Leukemia, Acute Nonlymphocytic,Leukemias, Acute Myeloblastic,Leukemias, Acute Myelocytic,Leukemias, Acute Myelogenous,Leukemias, Acute Myeloid,Leukemias, Acute Nonlymphoblastic,Leukemias, Acute Nonlymphocytic,Myeloblastic Leukemias, Acute,Myelocytic Leukemias, Acute,Myelogenous Leukemias, Acute,Myeloid Leukemias, Acute,Nonlymphoblastic Leukemias, Acute,Nonlymphocytic Leukemias, Acute

Related Publications

Costa Bachas, and Carolien Duetz, and Margot F van Spronsen, and Jan Verhoeff, and Juan J Garcia Vallejo, and Joop H Jansen, and Jacqueline Cloos, and Theresia M Westers, and Arjan A van de Loosdrecht
May 2022, Experimental hematology & oncology,
Costa Bachas, and Carolien Duetz, and Margot F van Spronsen, and Jan Verhoeff, and Juan J Garcia Vallejo, and Joop H Jansen, and Jacqueline Cloos, and Theresia M Westers, and Arjan A van de Loosdrecht
February 2013, Proceedings of the National Academy of Sciences of the United States of America,
Costa Bachas, and Carolien Duetz, and Margot F van Spronsen, and Jan Verhoeff, and Juan J Garcia Vallejo, and Joop H Jansen, and Jacqueline Cloos, and Theresia M Westers, and Arjan A van de Loosdrecht
September 2000, Blood,
Costa Bachas, and Carolien Duetz, and Margot F van Spronsen, and Jan Verhoeff, and Juan J Garcia Vallejo, and Joop H Jansen, and Jacqueline Cloos, and Theresia M Westers, and Arjan A van de Loosdrecht
October 2015, Zhongguo shi yan xue ye xue za zhi,
Costa Bachas, and Carolien Duetz, and Margot F van Spronsen, and Jan Verhoeff, and Juan J Garcia Vallejo, and Joop H Jansen, and Jacqueline Cloos, and Theresia M Westers, and Arjan A van de Loosdrecht
January 2017, Blood,
Costa Bachas, and Carolien Duetz, and Margot F van Spronsen, and Jan Verhoeff, and Juan J Garcia Vallejo, and Joop H Jansen, and Jacqueline Cloos, and Theresia M Westers, and Arjan A van de Loosdrecht
April 2023, bioRxiv : the preprint server for biology,
Costa Bachas, and Carolien Duetz, and Margot F van Spronsen, and Jan Verhoeff, and Juan J Garcia Vallejo, and Joop H Jansen, and Jacqueline Cloos, and Theresia M Westers, and Arjan A van de Loosdrecht
March 2020, Cytometry. Part B, Clinical cytometry,
Costa Bachas, and Carolien Duetz, and Margot F van Spronsen, and Jan Verhoeff, and Juan J Garcia Vallejo, and Joop H Jansen, and Jacqueline Cloos, and Theresia M Westers, and Arjan A van de Loosdrecht
January 2001, Cancer treatment and research,
Costa Bachas, and Carolien Duetz, and Margot F van Spronsen, and Jan Verhoeff, and Juan J Garcia Vallejo, and Joop H Jansen, and Jacqueline Cloos, and Theresia M Westers, and Arjan A van de Loosdrecht
January 1987, Immunologic research,
Costa Bachas, and Carolien Duetz, and Margot F van Spronsen, and Jan Verhoeff, and Juan J Garcia Vallejo, and Joop H Jansen, and Jacqueline Cloos, and Theresia M Westers, and Arjan A van de Loosdrecht
January 2018, PloS one,
Copied contents to your clipboard!